Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab.

Détails

ID Serval
serval:BIB_1E023D2305FE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab.
Périodique
Eye (london, England)
Auteur⸱e⸱s
Massamba N., Dirani A., Knoeri J., Pasquier B., Ingram A., Soubrane G.
ISSN
1476-5454 (Electronic)
ISSN-L
0950-222X
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
29
Numéro
11
Pages
1453-1457
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article
Publication Status: ppublish
Résumé
PURPOSE: To evaluate the impact of traditional French summer vacation on visual acuity and spectral domain-optical coherence tomography (SD-OCT) of Wet AMD patients being treated with intravitreal Ranibizumab.
METHODS: This was a consecutive, comparative, single-centre, prospective analysis. All patients who were being treated with intravitreal injection of 0.5 mg ranibizumab at Cergy Pontoise Hospital, Department of Ophthalmology between July 2013 and September 2014 were included. Patients were divided into two groups: (A) patients who skipped one ranibizumab intravitreal injection during holidays, and (B) patients who received injection during their holidays. Evaluations occurred prior to traditional holiday (baseline) and 2 months later, consisting of BCVA using ETDRS, and a complete ophthalmic examination that included slit-lamp biomicroscopy, fundus examination, fluorescein angiography (FA), indocyanine green angiography (ICGA), and spectral domain-optical coherence tomography (SD-OCT). All patients were being treated with PRN anti-VEGF regimen and criteria for reinjection included a visual acuity loss >5 ETDRS letters and/or an increase of central retinal thickness, presence of subretinal fluid, intraretinal fluid, or pigment epithelium detachment. If reinjection criteria were not met, patients were advised to return in 4 weeks.
RESULTS: The mean visual acuity change was -0.071 ± 0.149 (LogMAR) in group A and + 0.003 ± 0.178 in group B (P = 0.041). At the second visit (2 months after preholidays visit), 61.8% of patients in group A had SRF and/or intraretinal cysts, and only 27.6% of patients in group B. There was a significant difference in the persistence of fluid between the two groups (P = 0.007, χ(2)-test).
CONCLUSION: This cases series demonstrated the detrimental impact of holidays on visual acuity in patients treated with ranibizumab for AMD, which, in spite of their treatment regimen, still leave in vacation. Therefore, it is important to convey the message of treatment adherence to patients, despite their need of holidays.
Mots-clé
Aged, Aged, 80 and over, Angiogenesis Inhibitors/therapeutic use, Female, Fluorescein Angiography, Holidays, Humans, Intravitreal Injections, Male, Medication Adherence/statistics & numerical data, Patient Compliance, Prospective Studies, Ranibizumab/therapeutic use, Retreatment, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Visual Acuity/physiology, Wet Macular Degeneration/drug therapy, Wet Macular Degeneration/physiopathology
Pubmed
Web of science
Open Access
Oui
Création de la notice
15/12/2015 18:35
Dernière modification de la notice
20/08/2019 13:54
Données d'usage